1. |
|
|
2. |
- Drevinge, Christina, 1983, et al.
(author)
-
Perilipin 5 is protective in the ischemic heart
- 2016
-
In: International Journal of Cardiology. - : Elsevier BV. - 0167-5273 .- 1874-1754. ; 219, s. 446-454
-
Journal article (peer-reviewed)abstract
- Background: Myocardial ischemia is associated with alterations in cardiac metabolism, resulting in decreased fatty acid oxidation and increased lipid accumulation. Here we investigate how myocardial lipid content and dynamics affect the function of the ischemic heart, and focus on the role of the lipid droplet protein perilipin 5 (Plin5) in the pathophysiology of myocardial ischemia. Methods and results: We generated Plin5(-/-) mice and found that Plin5 deficiency dramatically reduced the triglyceride content in the heart. Under normal conditions, Plin5(-/-) mice maintained a close to normal heart function by decreasing fatty acid uptake and increasing glucose uptake, thus preserving the energy balance. However, during stress or myocardial ischemia, Plin5 deficiency resulted in myocardial reduced substrate availability, severely reduced heart function and increased mortality. Importantly, analysis of a human cohort with suspected coronary artery disease showed that a common noncoding polymorphism, rs884164, decreases the cardiac expression of PLIN5 and is associated with reduced heart function following myocardial ischemia, indicating a role for Plin5 in cardiac dysfunction. Conclusion: Our findings indicate that Plin5 deficiency alters cardiac lipid metabolism and associates with reduced survival following myocardial ischemia, suggesting that Plin5 plays a beneficial role in the heart following ischemia. (C) 2016 The Authors. Published by Elsevier Ireland Ltd.
|
|
3. |
- Hulten, A. H., et al.
(author)
-
First evaluation of a multicomponent flue gas cleaning concept using chlorine dioxide gas - Experiments on chemistry and process performance
- 2017
-
In: Fuel. - : Elsevier BV. - 0016-2361. ; 210, s. 885-891
-
Journal article (peer-reviewed)abstract
- This work has investigated a multi-pollutant flue gas cleaning concept based on oxidation using chlorine dioxide (ClO2) gas with subsequent absorption. The chlorine dioxide gas converts the relatively insoluble nitric oxide (NO) to the more soluble nitrogen dioxide (NO2). This makes a downstream wet scrubbing process feasible for simultaneous removal of sulphur oxides (SOx) and nitrogen dioxide (NO2). An experimental evaluation of the proposed process using chlorine dioxide gas has been performed on a laboratory scale. The experimental setup, designed and built by Akzo Nobel, consists of a reactor for oxidation, a flue gas condenser and a wet scrubber. The results show that ClO2 gas oxidises NO with high efficiencies under a wide range of process conditions, also in the presence of sulphur dioxide (SO2). The more ClO2 gas is added, the higher the degree of NO oxidation and the total nitrogen oxides (NOx) removal efficiency becomes. The results also show that the presence of water strongly increases the removal of SO2, which is believed to be an effect of liquid phase nitrogen-sulphur interactions. The absorption solution, sodium carbonate and sodium sulphite, is efficient in removing NOx (especially NO2) from the oxidised flue gas. The total NOx reduction at 0.6 ClO2:NO mole ratio and subsequent wet scrubbing is between 79% and 94%, depending on the process conditions used. The total SO2 reduction in the scrubber is between 97% and 100% independent of ClO2 gas addition. Furthermore, the total NOx balance shows that the major part of the NOx is converted to nitrate in the condensate liquor and as nitrite in the absorption solution. A higher ClO2 gas addition and a higher reactor temperature convert more of the NOx to nitrite in the absorption solution.
|
|
4. |
- Nenonen, Hannah, et al.
(author)
-
The N680S variant in the follicle-stimulating hormone receptor gene identifies hyperresponders to controlled ovarian stimulation
- 2019
-
In: Pharmacogenetics and Genomics. - 1744-6872. ; 29:5, s. 114-120
-
Journal article (peer-reviewed)abstract
- OBJECTIVE: To study if the follicle-stimulating hormone receptor (FSHR) variant asparagine/serine in amino acid 680 (N680S) can predict hypersensitivity to gonadotropins in women undergoing assisted reproduction.PATIENTS AND METHODS: In this retrospective study, 586 women undergoing their first in-vitro fertilisation treatment were enroled, and their FSHR N680S genetic variant was analysed. The main outcome measures were number of retrieved oocytes and any grade of ovarian hyperstimulation syndrome (OHSS). Experimental studies were performed on FSHR variants transfected into eukaryotic cells treated with 1-90 IU recombinant follicle-stimulating hormone. The receptors' ability to induce a second messenger 3',5'-cyclic AMP was measured.RESULTS: The proportion of women who developed OHSS was 6% (n=36). None of the women who developed this condition had the homozygous serine variant. The N680S polymorphism in the FSHR was associated with the condition, P trend (genotype)=0.004 and P allelic (alleles)=0.04. Mean oocyte number was 11±6 in women without OHSS and 16±8 in women who developed OHSS (P=0.001), despite exposure to lower total hormonal dose in the latter group. The odds ratio for developing OHSS in carriers of the asparagine allele was 1.7 (95% confidence interval: 1.025-2.839, P=0.04). A higher receptor activity in cells expressing asparagine compared with the serine was also evident at all concentrations of recombinant follicle-stimulating hormone used (P<0.05 for all).CONCLUSION: This study confirms previous findings regarding higher hormonal sensitivity in carriers of asparagine in the N680S position. These women are at higher risk for OHSS during in-vitro fertilisation. Genetic testing could identify those at highest risk to develop this adverse effect.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.
|
|
5. |
|
|
6. |
- Skiöldebrand, Eva, et al.
(author)
-
Cartilage oligomeric matrix protein neoepitope in the synovial fluid of horses with acute lameness: A new biomarker for the early stages of osteoarthritis
- 2017
-
In: Equine Veterinary Journal. - : Wiley. - 0425-1644 .- 2042-3306. ; 49:5, s. 662-667
-
Journal article (peer-reviewed)abstract
- BackgroundClinical tools to diagnose the early changes of osteoarthritis (OA) that occur in the articular cartilage are lacking. ObjectivesWe sought to identify and quantify a novel cartilage oligomeric matrix protein (COMP) neoepitope in the synovial fluid from the joints of healthy horses and those with different stages of OA. Study designIn vitro quantitative proteomics and assay development with application in synovial fluids samples obtained from biobanks of well-characterised horses. MethodsArticular cartilage explants were incubated with or without interleukin-1 for 25 days. Media were analysed via quantitative proteomics. Synovial fluid was obtained from either normal joints (n = 15) or joints causing lameness (n = 17) or with structural OA lesions (n = 7) and analysed for concentrations of the COMP neoepitope using a custom-developed inhibition enzyme-linked immunosorbent assay (ELISA). Explants were immunostained with polyclonal antibodies against COMP and the COMP neoepitopes. ResultsSemitryptic COMP peptides were identified and quantified in cell culture media from cartilage explants. A rabbit polyclonal antibody was raised against the neoepitope of the N-terminal portion of one COMP fragment (sequence SGPTHEGVC). An inhibition ELISA was developed to quantify the COMP neoepitope in synovial fluid. The mean concentration of the COMP neoepitope significantly increased in the synovial fluid from the joints responsible for acute lameness compared with normal joints and the joints of chronically lame horses and in joints with chronic structural OA. Immunolabelling for the COMP neoepitope revealed a pericellular staining in the interleukin-1-stimulated explants. Main limitationsThe ELISA is based on polyclonal antisera rather than a monoclonal antibody. ConclusionsThe increase in the COMP neoepitope in the synovial fluid from horses with acute lameness suggests that this neoepitope has the potential to be a unique candidate biomarker for the early molecular changes in articular cartilage associated with OA.
|
|
7. |
|
|